Sincalide (Synonyms: Cholecystokinin octapeptide; CCK-8; SQ19844)

Name: Sincalide
Brand: MedChemExpress
SKU: HY-P0093
Rating: 5.0 (4 reviews)

Cat. No.: HY-P0093 Purity: 99.30%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Sincalide (Cholecystokinin octapeptide, CCK-8) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. Sincalide is a major bioactive segment of CCK that retains most of the biological activities of CCK. Sincalide can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. Sincalide can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. Sincalide is a major bioactive segment of CCK that retains most of the biological activities of CCK.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

CAS No. : 25126-32-3

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 4 publication(s) in Google Scholar

Other Forms of Sincalide:

Sincalide ammonium In-stock

4 Publications Citing Use of MCE Sincalide

Bio/Physico-chemical Assay

Cell Imaging/Staining

RT-PCR

Cell Proliferation/Viability Assay

: Sincalide purchased from MedChemExpress. Usage Cited in: J Gene Med. 2025 Dec;27(12):e70063. [Abstract]; Sincalide (Cholecystokinin; CCK) increased the expression of IL-6, TNF-α, and IL-1β in 266-6 cells.

: Sincalide purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2022 Dec 31;12(1):100.; After transfection with GPX4 siRNA, mouse pancreatic acinar carcinoma 266-6 cells were treated with Sincalide (Cholecystokinin; CCK) (5 μM; 6 h), and lipid reactive oxygen species (ROS) levels and the extent of cell death were determined.

: Sincalide purchased from MedChemExpress. Usage Cited in: Immunogenetics. 2023 Feb;75(1):17-25. [Abstract]; Sincalide (CCK-8) (10 μL; 37 ℃; 2 h) was used to evaluate the proliferative ability of LUAD cells.

: Sincalide purchased from MedChemExpress. Usage Cited in: Immunogenetics. 2023 Feb;75(1):17-25. [Abstract]; Sincalide (CCK-8) (10 μL; 37 ℃; 2 h) was used to illustrate that si-IL4I1 + RO8191 had the ability to reverse the restraining impact of si-IL4I1 on LUAD cell proliferation.

: Sincalide purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2019 Aug:116:109001. [Abstract]; The OATP superfamily blocker Sincalide (SIN) (20 μM; 2 h) blocked Caba-780 uptake in renal cell carcinoma (RCC) cells.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Cholecystokinin Receptor Isoform Specific Products:

View All Isoforms

CCKAR CCKBR

View All PI3K Isoform Specific Products:

View All Isoforms

PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

View All Akt Isoform Specific Products:

View All Isoforms

Akt Akt1 Akt2 Akt3

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	0.63 nM Compound: CCK-8	Affinity against Cholecystokinin type B receptor expressed in CHO cells on rat brain. Affinity against Cholecystokinin type B receptor expressed in CHO cells on rat brain.	[PMID: 11020275]
CHO	EC₅₀	0.63 nM Compound: CCK8	Effective concentration for the stimulation of Inositol Phosphate accumulation in CHO cells expressing wild-type Cholecystokinin type B receptor Effective concentration for the stimulation of Inositol Phosphate accumulation in CHO cells expressing wild-type Cholecystokinin type B receptor	[PMID: 9057851]
CHO	IC₅₀	1.2 x 10^-10 M Compound: CCK-8s	Displacement of [125I]CCK-8s from human recombinant CCK-B receptor expressed in CHO cells Displacement of [125I]CCK-8s from human recombinant CCK-B receptor expressed in CHO cells	[PMID: 26988801]
CHO	IC₅₀	1.2 x 10^-10 M Compound: CCK-8s	Displacement of [125I]CCK-8s from human recombinant CCK2 receptor expressed in CHO cells measured after 60 mins by scintillation counting method Displacement of [125I]CCK-8s from human recombinant CCK2 receptor expressed in CHO cells measured after 60 mins by scintillation counting method	[PMID: 27876250]
CHO	IC₅₀	1.3 x 10^-10 M Compound: CCK-8s	Displacement of [125I]CCK-8s from human recombinant CCK-A receptor expressed in CHO cells Displacement of [125I]CCK-8s from human recombinant CCK-A receptor expressed in CHO cells	[PMID: 26988801]
CHO	IC₅₀	1.3 x 10^-10 M Compound: CCK-8s	Displacement of [125I]CCK-8s from human recombinant CCK1 receptor expressed in CHO cells measured after 60 mins by scintillation counting method Displacement of [125I]CCK-8s from human recombinant CCK1 receptor expressed in CHO cells measured after 60 mins by scintillation counting method	[PMID: 27876250]
HEK293	EC₅₀	27 nM Compound: CCK-8, SO3	Antagonist activity at CCK2 receptor expressed in HEK293 cells assessed as accumulation of [3H]inositol phosphates by PI assay Antagonist activity at CCK2 receptor expressed in HEK293 cells assessed as accumulation of [3H]inositol phosphates by PI assay	[PMID: 16686530]
HEK293	EC₅₀	28 nM Compound: CCK-8, SO3	Antagonist activity at CCK1 receptor expressed in HEK 293 cells assessed as accumulation of [3H]inositol phosphates by PI assay Antagonist activity at CCK1 receptor expressed in HEK 293 cells assessed as accumulation of [3H]inositol phosphates by PI assay	[PMID: 16686530]
Jurkat	EC₅₀	0.093 nM Compound: sincalide	Displacement of [125I]CCK-8 from CCK2 receptor in human FGS7 Jurkat cells Displacement of [125I]CCK-8 from CCK2 receptor in human FGS7 Jurkat cells	[PMID: 16562853]
Jurkat	EC₅₀	2 nM Compound: CCK-8S	Compound was evaluated for calcium mobilization in Jurkat cells Compound was evaluated for calcium mobilization in Jurkat cells	[PMID: 10866391]

In Vitro

Sincalide (Cholecystokinin octapeptide, CCK-8), as a novel cardiovascular hormone, has a significant inhibitory effect on myocardial fibrosis in noninfarcted areas. Sincalide also plays a positive role in fighting inflammation, apoptosis and collagen deposition. Sincalide protects H9c2 cardiomyoblasts from Ang II-induced apoptosis partly via activation of the CCK1 receptor and the phosphatidyqinositol-3 kinase/protein kinase B (PI3K/Akt) signaling pathway^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:	H9c2 cells
Concentration:	0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
Incubation Time:	24 h
Result:	Attenuated Ang II‐induced toxicity in H9c2 cells

Apoptosis Analysis^[3]

Cell Line:	H9c2 cells
Concentration:	0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
Incubation Time:	24 h
Result:	Decreased apoptotic cells, and prevented Ang II‐induced cytotoxicity that involves modulation of the PI3K/Akt pathway.

Western Blot Analysis^[3]

Cell Line:	H9c2 cells
Concentration:	0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
Incubation Time:	24 h
Result:	Expressed the protein and mRNAs of CCK and both its receptors in H9c2 cells.

RT-PCR^[3]

Cell Line:	H9c2 cells
Concentration:	0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
Incubation Time:	24 h
Result:	Increased the protein and mRNA expression levels of CCK and decreased CCK 1 receptor expression levels at both the protein and mRNA levels with Ang II stimulation markedly.

In Vivo

Sincalide (Cholecystokinin octapeptide, CCK-8) (i.p.; 50 μg/kg/d; for 4 weeks) alleviates fibrosis in the noninfarcted regions and delay the left ventricular remodeling and the progress of heart failure in a MI rat model^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MI rat model^[4]
Dosage:	50 μg/kg
Administration:	i.p.; 50 μg/kg/d; for 4 weeks
Result:	Had significant inhibitory effect on myocardial fibrosis in noninfarcted areas.

Molecular Weight

1143.27

Formula

C₄₉H₆₂N₁₀O₁₆S₃

CAS No.

25126-32-3

Appearance

Solid

Color

White to off-white

Sequence

Asp-{SO3H-Tyr}-Met-Gly-Trp-Met-Asp-Phe-NH2

Sequence Shortening

D-{SO3H-Tyr}-MGWMDF-NH2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture and light, under nitrogen

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

Solvent & Solubility

In Vitro:

H₂O : 50 mg/mL (43.73 mM; ultrasonic and adjust pH to 11 with NH3·H2O)

DMF : 50 mg/mL (43.73 mM; Need ultrasonic)

DMSO : 25 mg/mL (21.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.8747 mL	4.3734 mL	8.7468 mL
5 mM	0.1749 mL	0.8747 mL	1.7494 mL
10 mM	0.0875 mL	0.4373 mL	0.8747 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.19 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (2.19 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 3

Add each solvent one by one: 10% DMF 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (2.19 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.30%

Select Batch:

Data Sheet (282 KB) SDS (394 KB)

COA (250 KB) RP-HPLC (225 KB) MS (262 KB) Elemental Analysis Report (110 KB)

Handling Instructions (2659 KB)

References

[1]. Maher KA et al. Kinevac (sincalide for injection)/Squibb Diagnostics. Gastroenterol Nurs. 1991 Oct;14(2):98-100. [Content Brief]

[2]. Ziessman HA. Sincalide: A Review of Clinical Utility, Proper Infusion Methodology, and Alternative Cholecystogogues. J Nucl Med Technol. 2019 Sep;47(3):210-212. [Content Brief]

[3]. Can Wang, et al. Protective effect of cholecystokinin octapeptide on angiotensin II-induced apoptosis in H9c2 cardiomyoblast cells. J Cell Biochem. 2020 Jul;121(7):3560-3569. [Content Brief]

[4]. Can Wang, et al. Cholecystokinin octapeptide reduces myocardial fibrosis and improves cardiac remodeling in post myocardial infarction rats. Int J Biochem Cell Biol. 2020 Aug;125:105793. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / H₂O / DMF	1 mM	0.8747 mL	4.3734 mL	8.7468 mL	21.8671 mL
	5 mM	0.1749 mL	0.8747 mL	1.7494 mL	4.3734 mL
	10 mM	0.0875 mL	0.4373 mL	0.8747 mL	2.1867 mL
	15 mM	0.0583 mL	0.2916 mL	0.5831 mL	1.4578 mL
	20 mM	0.0437 mL	0.2187 mL	0.4373 mL	1.0934 mL
H₂O / DMF	25 mM	0.0350 mL	0.1749 mL	0.3499 mL	0.8747 mL
	30 mM	0.0292 mL	0.1458 mL	0.2916 mL	0.7289 mL
	40 mM	0.0219 mL	0.1093 mL	0.2187 mL	0.5467 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Sincalide Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Sincalide (Synonyms: Cholecystokinin octapeptide; CCK-8; SQ19844)

Customer Review

Other Forms of Sincalide:

Sincalide Related Antibodies

4 Publications Citing Use of MCE Sincalide

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Cholecystokinin Receptor Isoform Specific Products:

View All PI3K Isoform Specific Products:

View All Akt Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Sincalide Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Sincalide Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report